4//SEC Filing
Shah Jatin 4
Accession 0001209191-21-009138
CIK 0001503802other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 9:56 PM ET
Size
11.8 KB
Accession
0001209191-21-009138
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2021-02-05−5,650→ 16,950 total→ Common Stock (5,650 underlying) - Exercise/Conversion
Common Stock
2021-02-05+5,650→ 49,875 total
Footnotes (3)
- [F1]Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- [F2]Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2020.
- [F3]On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001782186
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 9:56 PM ET
- Size
- 11.8 KB